Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $46.70 and last traded at $46.47, with a volume of 385082 shares changing hands. The stock had previously closed at $45.07.
Gemini Therapeutics Stock Performance
The stock has a market cap of $1.80 billion, a PE ratio of -41.62 and a beta of -0.12. The company’s 50-day moving average price is $35.19 and its 200 day moving average price is $49.59.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Investing In Automotive Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Financial Services Stocks Investing
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}
